What type of stem cells are used in your Stem Cell Therapy for Stroke?
For stroke recovery, Stem Cell Mexico uses allogeneic mesenchymal stromal cells (MSCs) derived from Wharton's jelly, the connective tissue of donated umbilical cords, most commonly administered by intravenous (IV) infusion.

These cells are not meant to rebuild the area of the brain that was lost in the stroke. They are used for their ability to reduce inflammation, modulate the immune system, release neurotrophic factors that support surviving neurons, and promote the formation of small blood vessels, which together may help create a better environment for recovery and rehabilitation. Cells are prepared in a licensed laboratory, with quality and safety testing before release, and documented for each patient.
Many different cell types have been studied for stroke, with different routes and results. This guide explains what has been tried, why we use umbilical cord MSCs, and how to interpret the evidence.
What happens in the brain after a stroke
An ischemic stroke occurs when a blood vessel supplying the brain is blocked, depriving brain tissue of oxygen. Neurons in the core of the affected area die within minutes to hours. Around this core lies a region that is injured but may survive, and in the following days and weeks a secondary process unfolds: inflammation, swelling, breakdown of the blood-brain barrier and loss of connections between neurons.
Recovery depends largely on neuroplasticity, the brain's ability to reorganize, form new connections and recruit other areas to take over lost functions. Intensive rehabilitation is the most powerful way to drive this process. Cell therapies are being studied as a way to support and enhance it.
Cell types studied in stroke
Bone marrow mononuclear cells
A mixture of cells obtained from the patient's own bone marrow, given intravenously or into an artery shortly after stroke. Early studies showed safety, and functional results varied in larger trials.
Multipotent adult progenitor cells (MAPCs)
A bone-marrow-derived cell product tested in the MASTERS trial, published in The Lancet Neurology in 2017. Cells were given intravenously within one to two days after ischemic stroke. The treatment was safe and well tolerated. Exploratory analyses suggested more benefit when cells were given earlier, which led to further trials.
Bone marrow and adipose MSCs
Autologous or donor MSCs have been studied in the subacute and chronic phases, mostly in small trials, with good safety and variable effects on neurological scores.
Genetically modified or neural stem cells
Some products, such as modified bone marrow cells or neural stem cell lines, have been implanted surgically near the stroke area in chronic patients. These approaches require neurosurgery and are available only in clinical trials.
Umbilical cord-derived MSCs
Umbilical cord MSCs, including Wharton's jelly MSCs, are increasingly studied because they are young, can be expanded to defined doses and have a strong secretion profile. This is the cell type used at Stem Cell Mexico.
Why Wharton's jelly MSCs
- Neurotrophic and regenerative signals: a comparative study in Scientific Reports (Petrenko and colleagues, 2020) found that Wharton's jelly MSCs secreted higher levels of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), hepatocyte growth factor (HGF) and fibroblast growth factor 2 than bone marrow MSCs. Bone marrow MSCs secreted more vascular endothelial growth factor (VEGF), and MSCs from all sources stimulated nerve fiber growth in the laboratory.
- Fast growth and consistent dosing: these cells expand efficiently, allowing defined doses.
- Young source: most stroke survivors are older adults, and cells from newborn tissue avoid the decline in quality seen with older donors or the patient's own aged cells.
- No harvesting procedure: no bone marrow aspiration or liposuction is needed, which is especially helpful for patients with limited mobility or on blood thinners.
- No donor matching required, because MSCs have low immunogenicity.
How the cells may support recovery
Researchers have identified several ways MSCs could help after a stroke. First, they can shift immune cells in the brain and blood away from a prolonged inflammatory state, which may limit secondary damage. Second, they release neurotrophic factors that help surviving neurons stay healthy and form new connections. Third, they stimulate angiogenesis, the growth of small blood vessels, which can improve blood supply around the injured area. Fourth, they release extracellular vesicles carrying proteins and genetic material that influence nearby cells. Finally, some animal studies suggest MSCs may support the brain's own stem cells in producing new neural cells. None of these mechanisms replaces the tissue lost in the stroke core, but together they may make the brain more responsive to rehabilitation.
How the cells are given
At Stem Cell Mexico, stroke protocols most commonly use IV infusion, which is minimally invasive. After an IV infusion, many cells are temporarily filtered by the lungs before being cleared, and their effects on the brain are believed to occur largely through circulating signals, immune modulation and the release of extracellular vesicles. Other routes studied in research include intra-arterial delivery (closer to the brain, with a risk of small vessel blockages) and direct surgical implantation (more targeted, with neurosurgical risks).
What the evidence says
Cochrane systematic review (2019): Seven randomized trials with 401 participants with ischemic stroke showed that stem cell transplantation was associated with reduced neurological impairment on the NIH Stroke Scale, but not with better functional independence on the modified Rankin Scale or Barthel Index. No major safety concerns were identified.
MASTERS trial (2017): Showed that an IV bone-marrow-derived cell product was safe in acute stroke, with exploratory signals of benefit when given very early.
What this means: Cell therapy for stroke has a reassuring safety record and signals of neurological improvement, with results that vary between patients. Results also vary by cell type, timing and route, so findings from one approach should not be assumed for another. Umbilical cord MSC therapy for chronic stroke is offered as a supportive approach alongside rehabilitation.
Regulatory context
No stem cell product is approved by the FDA or the European Medicines Agency for stroke. In Mexico, establishments that handle stem cells operate under sanitary licenses from COFEPRIS.
Timing: acute, subacute and chronic stroke
- Acute (first days): most large cell trials, including MASTERS, have focused here. These treatments are given in hospitals as part of research protocols.
- Subacute (weeks to months): the brain is still highly plastic, and rehabilitation gains are greatest.
- Chronic (after six months): recovery slows, and this is when most patients consider regenerative treatment. Goals are usually specific and incremental.
At Stem Cell Mexico, most patients are in the subacute or chronic phase, once they are medically stable.
Who may be a candidate
- Medically stable after an ischemic stroke, without a recent new stroke or transient ischemic attack.
- Controlled blood pressure, heart rhythm and diabetes.
- Careful review of blood thinners and bleeding risk.
- No active infection and no cancer history within the past five years.
- Specific goals and access to rehabilitation after treatment.
Hemorrhagic strokes require a more cautious, individual assessment.
What results patients and families commonly ask about
What improvements are possible? When changes occur, families often describe better endurance, reduced stiffness, improved hand control or clearer speech. Changes are usually gradual and partial.
When should we evaluate progress? Typically over three to six months, using therapist assessments and standardized scales compared with a pre-treatment baseline.
Does rehabilitation still matter? Yes. Rehabilitation is essential to turn biological changes into functional gains.
Preparing for treatment
Share recent brain imaging, neurology and rehabilitation reports, and a complete medication list. Blood thinners and antiplatelet drugs should never be stopped on your own; the medical team will review them with you. Let us know about mobility needs, swallowing difficulties or communication challenges so transportation, meals and support can be planned. Recording a short baseline, such as a walking video, grip strength or a speech sample, helps measure changes afterward.
Risks and limitations
IV MSC infusions are generally well tolerated. Possible effects include temporary fever, headache or fatigue, and rare risks include allergic reactions and thrombotic events, which is why screening and monitoring are important after a stroke. Results vary between patients.
Questions to ask during your evaluation
- Why are Wharton's jelly MSCs used rather than other cell types?
- What dose and route will be used, and why?
- What goals are realistic for my type and stage of stroke?
- How should treatment be coordinated with my neurologist and therapists?
- What documentation will I receive about the cells?
When stroke patients ask us by email which cells we use, our answer is the same as for every condition: allogeneic mesenchymal stem cells from the Wharton's jelly of donated umbilical cords, processed in a COFEPRIS-licensed laboratory. For stroke, they are usually given by IV infusion and, in selected cases after the doctor reviews your medical reports, by an additional intrathecal application.
Bottom line
For stroke, Stem Cell Mexico uses allogeneic Wharton's jelly MSCs, usually by IV infusion, to support the brain's recovery environment through anti-inflammatory and neurotrophic signals. Evidence shows good safety and signals of neurological improvement, while functional benefits continue to be studied. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your stroke recovery, goals and medical history.
References
- Cochrane: Boncoraglio GB et al. Stem cell transplantation for ischemic stroke, 2019 (opens in a new tab)
- Hess DC et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology, 2017 (opens in a new tab)
- Petrenko Y et al. A comparative analysis of multipotent mesenchymal stromal cells derived from different sources, with a focus on neuroregenerative potential. Scientific Reports, 2020 (opens in a new tab)
